Streaming Media

Type of Proposal

Oral presentation

Start Date

24-3-2015 10:00 AM

End Date

24-3-2015 10:50 AM

Faculty

Schulich School of Medicine Windsor

Faculty Sponsor

SROP- Schulich School of Medicine and Dentistry

Importance of the Project

Through my research, it is hoped to establish a new standard of care at Windsor Regional Hospital for high risk localized prostate cancer. We have shown a benefit to treating this disease with high dose rate brachytherapy in addition to external beam radiation treatment as opposed to the current standard of care which is external beam radiation treatment only.

Existing State of Knowledge

There has been one prior randomized control trial published recently that compared the two types of radiation therapy being studied in our study. This groups research demonstrated an increase relapse-free survival in patients treated with HDR-brachytherapy in conjunction with EBRT compared with those treated with EBRT alone. We planned to demonstrate these same findings in our patient population.

Research Question

We aimed to demonstrate there is a significant increase in relapse-free survival in high risk localized prostate cancer patients treated with HDR-brachytherapy in conjunction with EBRT compared with EBRT alone.

Methodology

A retrospective chart review was completed on a sample of 324 patients who were treated at a regional cancer centre in southwestern Ontario between 2001 and 2014. These patients were classified as high-risk according to the American Urological Association and European Association of Urology of having clinical or pathological staging T2c/T3a or Gleason score of 8-10 or Prostate Specific Antigen (PSA) ≥ 20 ng/mL. Of the 324 patients, 53 received HDR-BT with EBRT and 271 received EBRT only. Relapse was defined using the Phoenix definition of PSA rise 2 ng/mL above the nadir. The primary and secondary endpoints of the study were relapse free survival (RFS) and overall survival (OS).

Your Findings

The mean age of the study sample was 78 years (SD ± 8.1) with a mean pre-treament PSA of 17.98 (SD ± 15.79). While relapse occurred in 43 of the 271 patients who received EBRT, only 3 of the 53 patients who received HDR relapsed. Kaplan Meier survival analysis suggested that by the end of the 5 year follow up, more than 50% of patients in each of the study groups were relapse free; and thus median survival was not calculable. The mean time to relapse between the EBRT and HDR groups was (53.7 and 58.5 months, respectively; Log rank = 3.82, p = 0.05).

Share

COinS
 
Mar 24th, 10:00 AM Mar 24th, 10:50 AM

A RETROSPECTIVE COMPARISON OF HIGH DOSE RATE BRACHYTHERAPY AND EXTERNAL BEAM RADIOTHERAPY IN THE TREATMENT OF HIGH RISK CLINICALLY LOCALIZED PROSTATE CANCER AT THE WINDSOR REGIONAL HOSPITAL DURING 2001-2014.